Traders bought shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Thursday. $92.69 million flowed into the stock on the tick-up and $79.39 million flowed out of the stock on the tick-down, for a money net flow of $13.30 million into the stock. Of all stocks tracked, Gilead Sciences had the 16th highest net in-flow for the day. Gilead Sciences traded down ($0.27) for the day and closed at $81.55
GILD has been the subject of a number of analyst reports. Mizuho raised their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. JPMorgan Chase & Co. set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Maxim Group set a $94.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Monday, December 11th. Credit Suisse Group restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Vetr downgraded Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $90.00 target price for the company. in a report on Wednesday, January 17th. One equities research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $87.04.
The firm has a market cap of $104,290.00, a price-to-earnings ratio of 23.19, a P/E/G ratio of -1.87 and a beta of 1.22. The company has a debt-to-equity ratio of 1.10, a quick ratio of 3.48 and a current ratio of 3.55.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.78 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.67 by $0.11. The firm had revenue of $5.95 billion during the quarter, compared to the consensus estimate of $5.71 billion. Gilead Sciences had a return on equity of 50.29% and a net margin of 17.73%. The company’s quarterly revenue was down 18.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.70 earnings per share. equities analysts predict that Gilead Sciences, Inc. will post 6.24 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 29th. Stockholders of record on Friday, March 16th will be issued a dividend of $0.57 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Thursday, March 15th. This represents a $2.28 annualized dividend and a dividend yield of 2.83%. Gilead Sciences’s payout ratio is currently 59.77%.
In related news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $74.98, for a total transaction of $5,498,508.34. Following the transaction, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP James R. Meyers sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $80.24, for a total value of $8,024,000.00. Following the transaction, the executive vice president now directly owns 102,715 shares in the company, valued at approximately $8,241,851.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 418,333 shares of company stock valued at $32,742,108. Corporate insiders own 1.30% of the company’s stock.
Several large investors have recently made changes to their positions in GILD. GW Henssler & Associates Ltd. boosted its position in shares of Gilead Sciences by 8.0% during the second quarter. GW Henssler & Associates Ltd. now owns 160,509 shares of the biopharmaceutical company’s stock valued at $11,361,000 after buying an additional 11,880 shares during the last quarter. Highstreet Asset Management Inc. purchased a new position in shares of Gilead Sciences during the second quarter valued at approximately $1,193,000. Ballentine Partners LLC boosted its position in shares of Gilead Sciences by 63.4% during the second quarter. Ballentine Partners LLC now owns 8,549 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 3,318 shares during the last quarter. Aspiriant LLC boosted its position in Gilead Sciences by 32.3% in the second quarter. Aspiriant LLC now owns 3,894 shares of the biopharmaceutical company’s stock worth $276,000 after purchasing an additional 950 shares during the last quarter. Finally, Cornerstone Capital Inc. boosted its position in Gilead Sciences by 7.1% in the second quarter. Cornerstone Capital Inc. now owns 49,166 shares of the biopharmaceutical company’s stock worth $3,480,000 after purchasing an additional 3,260 shares during the last quarter. 76.47% of the stock is currently owned by institutional investors.
About Gilead Sciences
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.